Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles - PubMed (original) (raw)

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles

Shanta Dhar et al. Proc Natl Acad Sci U S A. 2008.

Abstract

Cisplatin is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and acquired resistance limit its application in many types of cancer including prostate. We report a unique strategy to deliver cisplatin to prostate cancer cells by constructing Pt(IV)-encapsulated prostate-specific membrane antigen (PSMA) targeted nanoparticles (NPs) of poly(D,L-lactic-co-glycolic acid) (PLGA)-poly(ethylene glycol) (PEG)-functionalized controlled release polymers. By using PLGA-b-PEG nanoparticles with PSMA targeting aptamers (Apt) on the surface as a vehicle for the platinum(IV) compound c,t,c-[Pt(NH(3))(2)(O(2)CCH(2)CH(2)CH(2)CH(2)CH(3))(2)Cl(2)] (1), a lethal dose of cisplatin was delivered specifically to prostate cancer cells. PSMA aptamer targeted delivery of Pt(IV) cargos to PSMA(+) LNCaP prostate cancer cells by endocytosis of the nanoparticle vehicles was demonstrated using fluorescence microscopy by colocalization of green fluorescent labeled cholesterol-encapsulated NPs and early endosome marker EEA-1. The choice of linear hexyl chains in 1 was the result of a systematic study to optimize encapsulation and controlled release from the polymer without compromising either feature. Release of cisplatin from the polymeric nanoparticles after reduction of 1 and formation of cisplatin 1,2-intrastrand d(GpG) cross-links on nuclear DNA was confirmed by using a monoclonal antibody for the adduct. A comparison between the cytotoxic activities of Pt(IV)-encapsulated PLGA-b-PEG NPs with the PSMA aptamer on the surface (Pt-NP-Apt), cisplatin, and the nontargeted Pt(IV)-encapsulated NPs (Pt-NP) against human prostate PSMA-overexpressing LNCaP and PSMA(-) PC3 cancer cells revealed significant differences. The effectiveness of PSMA targeted Pt-NP-Apt nanoparticles against the PSMA(+) LNCaP cells is approximately an order of magnitude greater than that of free cisplatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1.

Scheme 1.

Chemical structure of the hydrophobic platinum(IV) compound 1 and the chemistry by which the active drug, cisplatin is released, after reduction in the cell.

Fig. 1.

Fig. 1.

Construction and properties of aptamer-functionalized Pt(IV) nanoparticles. (A) Synthesis of Pt(IV)-encapsulated PLGA-_b_-PEG-COOH nanoparticles by nanoprecipitation and conjugation of PSMA aptamer to NP. (B) Loading of 1 in the PLGA-_b_-PEG-COOH nanoparticles. (C) Size of the Pt(IV)-encapsulated nanoparticles.

Fig. 2.

Fig. 2.

In vitro release kinetics of encapsulated Pt(IV) compound 1 from PLGA-_b_-PEG nanoparticles in PBS (pH 7.4) at 37 °C.

Fig. 3.

Fig. 3.

Detection of endosome formation and cellular uptake of Pt-NP-Apt in LNCaP cells by fluorescence microscopy. Green fluorescent 22-NBD-cholesterol and 1 were encapsulated in the PLGA-_b_-PEG nanoparticles and PSMA aptamers were conjugated to the surface of the particles. The early endosomes were visualized in red by using the early endosome marker EEA-1.

Fig. 4.

Fig. 4.

Cytotoxicity profiles of PSMA aptamer-targeted Pt(IV)-encapsulated PLGA-_b_-PEG nanoparticles (Pt-NP-Apt) (red circles), nontargeted nanoparticles (Pt-NP) (black squares), and compound 1 (blue triangles) with (A) PSMA+ LNCaP cells and (B) PSMA− PC3 cells after 72 h as determined by the MTT assay.

Similar articles

Cited by

References

    1. Jemal A, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–230. - PubMed
    1. Murphy GP, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259–2269. - PubMed
    1. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997;57:2321–2324. - PubMed
    1. Wright GL, Jr, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–334. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources